The Perioperative Biochemical and Clinical Considerations of Pheochromocytoma Management
Open Access
- 25 June 2025
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (13) , 6080
Abstract
Pheochromocytoma, a rare catecholamine-secreting tumor, poses significant perioperative challenges due to its potential for severe hemodynamic instability. Careful management of patients with pheochromocytoma is critical for patient safety and favorable outcomes. The diagnostic workup focuses on biochemical analysis of plasma or urinary metanephrines, followed by imaging for tumor localization and genetic testing to identify hereditary syndromes. Preoperative management emphasizes adequate alpha-adrenergic blockade followed by beta-blockade to stabilize cardiovascular function. Anesthetic planning requires meticulous attention to volume status, cardiovascular optimization, and intraoperative monitoring to mitigate the risks of hypertensive crises and hypotension. Postoperative care must account for ongoing hemodynamic and metabolic fluctuations. A multidisciplinary, protocol-driven approach is essential to improve outcomes in patients undergoing pheochromocytoma resection. This paper provides a comprehensive overview of the genetic, biochemical, clinical, and anesthetic considerations involved in the diagnosis and perioperative management of pheochromocytoma.Keywords
This publication has 107 references indexed in Scilit:
- The role of methylation quantification of circulating tumor DNA (ctDNA) as a diagnostic biomarker of Pheochromocytomas (PCCs) and Paragangliomas (PGLs)Journal of Diabetes & Metabolic Disorders, 2024
- Role of epigenetic regulation on catecholamine synthesis in pheochromocytoma and paragangliomaCancer, 2024
- Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment optionsCancer Medicine, 2023
- Forty years of the adrenal chromaffin cell through ISCCB meetings around the worldPflügers Archiv - European Journal of Physiology, 2023
- Prognostic value of [18F]FDG-PET prior to [131I]MIBG treatment for pheochromocytoma and paraganglioma (PPGL)Annals of Nuclear Medicine, 2022
- Protocol for presurgical and anesthetic management of pheochromocytomas and sympathetic paragangliomas: a multidisciplinary approachJournal of Endocrinological Investigation, 2021
- Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paragangliomaEndocrine, 2017
- SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paragangliomaInternational Journal of Cancer, 2014
- The Diagnostic Evaluation and Multidisciplinary Management of Neurofibromatosis 1 and Neurofibromatosis 2JAMA, 1997
- Cytogenetic abnormalities in tumors of patients with von hippel-lindau diseaseCancer Genetics and Cytogenetics, 1989